Therapeutic Class
Targeted Therapy
31 drug groups 9 with data 1,449 patients
| Drug group | Drugs | Patients |
|---|---|---|
| AKT inhibitor PI3K/AKT/mTOR Pathway Inhibitors | 1 | no data |
| ALK targeting TKI Tyrosine Kinase Inhibitors (TKIs) | 5 | 12 |
| Aurora A kinase inhibitor Other Targeted Agents | 1 | 17 |
| BRAF inhibitor BRAF/MEK Pathway Inhibitors | 4 | 24 |
| CDK4/6 inhibitor CDK4/6 Inhibitors | 3 | 3 |
| ClpP protease activator Other Targeted Agents | 1 | no data |
| CSF1R targeting TKI Tyrosine Kinase Inhibitors (TKIs) | 1 | no data |
| EGFR targeting TKI Tyrosine Kinase Inhibitors (TKIs) | 9 | 486 |
| EZH2 inhibitor Epigenetic Modifiers | 1 | no data |
| FAK/Pyk2 inhibitor Other Targeted Agents | 1 | no data |
| FGFR targeting TKI Tyrosine Kinase Inhibitors (TKIs) | 4 | no data |
| Gamma-secretase inhibitor Other Targeted Agents | 1 | no data |
| Hedgehog Pathway Inhibitors Hedgehog Pathway Inhibitors | 2 | no data |
| HER(2) targeting TKI Tyrosine Kinase Inhibitors (TKIs) | 4 | no data |
| HIF-2α inhibitor HIF inhibitors | 1 | no data |
| IDH inhibitor IDH inhibitors | 2 | no data |
| JAK inhibitor JAK-STAT inhibitors | 1 | no data |
| KRAS Inhibitors KRAS inhibitors | 2 | no data |
| MEK inhibitor BRAF/MEK Pathway Inhibitors | 3 | combination data only |
| MET targeting TKI Tyrosine Kinase Inhibitors (TKIs) | 2 | no data |
| mTOR PI3K/AKT/mTOR Pathway Inhibitors | 3 | 11 |
| Multi-target TKI Tyrosine Kinase Inhibitors (TKIs) | 16 | 770 |
| PARP inhibitor PARP inhibitors | 4 | 125 |
| PI3K inhibitor PI3K/AKT/mTOR Pathway Inhibitors | 2 | no data |
| RAF–MEK clamp BRAF/MEK Pathway Inhibitors | 1 | no data |
| RET targeting TKI Tyrosine Kinase Inhibitors (TKIs) | 2 | no data |
| ROS1 targeting TKI Tyrosine Kinase Inhibitors (TKIs) | 1 | no data |
| Somatostatin analog Other Targeted Agents | 1 | no data |
| TRK targeting TKI Tyrosine Kinase Inhibitors (TKIs) | 1 | no data |
| VEGF-trap Anti-VEGF | 1 | no data |
| VEGFR targeting TKI Tyrosine Kinase Inhibitors (TKIs) | 3 | 1 |
Patients treated with the drug group as the sole drug class within 30 days of SRT. Combination therapies are shown on each group's page.